相似文献
1
Targeting Host Innate and Adaptive Immunity to Achieve the Functional Cure of Chronic Hepatitis B.靶向宿主固有免疫和适应性免疫以实现慢性乙型肝炎的功能性治愈
Vaccines (Basel). 2020 May 11;8(2):216. doi: 10.3390/vaccines8020216.
2
Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection.靶向固有和适应性免疫系统以治愈慢性乙型肝炎病毒感染的研究进展。
Front Immunol. 2020 Feb 7;10:3127. doi: 10.3389/fimmu.2019.03127. eCollection 2019.
3
Current and novel modalities for management of chronic hepatitis B infection.慢性乙型肝炎感染管理的当前及新型方法。
World J Hepatol. 2023 May 27;15(5):585-608. doi: 10.4254/wjh.v15.i5.585.
4
Toward Curative Immunomodulation Strategies for Chronic Hepatitis B Virus Infection.迈向慢性乙型肝炎病毒感染的治愈性免疫调节策略
ACS Infect Dis. 2019 May 10;5(5):703-712. doi: 10.1021/acsinfecdis.8b00297. Epub 2019 Apr 3.
5
Immunopathogenesis of Hepatitis B Virus.乙型肝炎病毒的免疫发病机制
J Infect Dis. 2017 Nov 16;216(suppl_8):S765-S770. doi: 10.1093/infdis/jix356.
6
Hepatitis B virus: new therapeutic perspectives.乙型肝炎病毒：新的治疗前景。
Liver Int. 2016 Jan;36 Suppl 1:85-92. doi: 10.1111/liv.13003.
7
Review article: novel therapies for hepatitis B virus cure - advances and perspectives.综述文章：乙肝病毒治愈的新型疗法——进展与展望
Aliment Pharmacol Ther. 2016 Aug;44(3):213-22. doi: 10.1111/apt.13694. Epub 2016 Jun 15.
8
Hepatitis B: progress in understanding chronicity, the innate immune response, and cccDNA protection.乙型肝炎：在理解慢性化、先天免疫反应及共价闭合环状DNA保护方面取得的进展
Ann Transl Med. 2016 Sep;4(18):337. doi: 10.21037/atm.2016.08.54.
9
Toward a Cure for Hepatitis B Virus Infection: Combination Therapy Involving Viral Suppression and Immune Modulation and Long-term Outcome.迈向治愈乙型肝炎病毒感染：涉及病毒抑制和免疫调节的联合疗法及长期结果
J Infect Dis. 2017 Nov 16;216(suppl_8):S771-S777. doi: 10.1093/infdis/jix355.
10
Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues.慢性乙型肝炎病毒感染过程中肝细胞癌的风险及核苷（酸）类似物治疗的保护作用。
World J Hepatol. 2015 May 18;7(8):1064-73. doi: 10.4254/wjh.v7.i8.1064.
引用本文的文献
1
TLR agonists as vaccine adjuvants in the prevention of viral infections: an overview.Toll样受体激动剂作为预防病毒感染的疫苗佐剂：概述
Front Microbiol. 2023 Dec 21;14:1249718. doi: 10.3389/fmicb.2023.1249718. eCollection 2023.
2
Effects of neddylation on viral infection: an overview.泛素化修饰对病毒感染的影响：概述。
Arch Virol. 2023 Dec 11;169(1):6. doi: 10.1007/s00705-023-05930-3.
3
Delivery Tools for Clustered Regularly Interspaced Short Palindromic Repeat/Associated Protein 9-Mediated Inhibition of Hepatitis B Virus Infection: An Update.用于成簇规律间隔短回文重复序列/相关蛋白9介导的乙型肝炎病毒感染抑制的递送工具：最新进展
Front Microbiol. 2022 Jul 1;13:953218. doi: 10.3389/fmicb.2022.953218. eCollection 2022.
4
Toll-Like Receptor Response to Hepatitis B Virus Infection and Potential of TLR Agonists as Immunomodulators for Treating Chronic Hepatitis B: An Overview.Toll 样受体对乙型肝炎病毒感染的反应及 TLR 激动剂作为治疗慢性乙型肝炎免疫调节剂的潜力：综述。
Int J Mol Sci. 2021 Sep 28;22(19):10462. doi: 10.3390/ijms221910462.
5
Treatments for HBV: A Glimpse into the Future.HBV 的治疗方法：未来展望。
Viruses. 2021 Sep 4;13(9):1767. doi: 10.3390/v13091767.
6
Recent Advances in Hepatitis B Treatment.乙型肝炎治疗的最新进展
Pharmaceuticals (Basel). 2021 May 1;14(5):417. doi: 10.3390/ph14050417.
7
Hepatitis B virus-host interactions and novel targets for viral cure.乙型肝炎病毒-宿主相互作用和新的病毒治愈靶点。
Curr Opin Virol. 2021 Aug;49:41-51. doi: 10.1016/j.coviro.2021.04.009. Epub 2021 May 22.
8
Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery.用于高效抗病毒药物发现的药物重新利用策略、进展与挑战
Front Pharmacol. 2021 May 4;12:660710. doi: 10.3389/fphar.2021.660710. eCollection 2021.
9
Safety, tolerability, pharmacokinetics, and pharmacodynamics of a TLR7 agonist prodrug RO6870868 in healthy volunteers.TLR7 激动剂前药 RO6870868 在健康志愿者中的安全性、耐受性、药代动力学和药效学。
Clin Transl Sci. 2021 Jul;14(4):1524-1534. doi: 10.1111/cts.13016. Epub 2021 Apr 9.
10
[Immunotherapies for the treatment of chronic hepatitis B virus infections-an overview with a focus on CAR T cells].[用于治疗慢性乙型肝炎病毒感染的免疫疗法——以嵌合抗原受体T细胞为重点的概述]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020 Nov;63(11):1357-1364. doi: 10.1007/s00103-020-03223-7. Epub 2020 Sep 29.
本文引用的文献
1
Challenges of CAR- and TCR-T cell-based therapy for chronic infections.基于嵌合抗原受体（CAR）和 T 细胞受体（TCR）的细胞疗法治疗慢性感染的挑战。
J Exp Med. 2020 May 4;217(5). doi: 10.1084/jem.20191663.
2
Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection.靶向固有和适应性免疫系统以治愈慢性乙型肝炎病毒感染的研究进展。
Front Immunol. 2020 Feb 7;10:3127. doi: 10.3389/fimmu.2019.03127. eCollection 2019.
3
HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection.在慢性乙型肝炎感染期间，HBeAg血清学转换与更有效的程序性死亡受体配体1（PD-L1）阻断相关。
JHEP Rep. 2019 Jun 28;1(3):170-178. doi: 10.1016/j.jhepr.2019.06.001. eCollection 2019 Sep.
4
Innate and adaptive immunity associated with resolution of acute woodchuck hepatitis virus infection in adult woodchucks.先天免疫和适应性免疫与成年土拨鼠急性 woodchuck 肝炎病毒感染的消退有关。
PLoS Pathog. 2019 Dec 23;15(12):e1008248. doi: 10.1371/journal.ppat.1008248. eCollection 2019 Dec.
5
Intranasal vaccination with HBs and HBc protein combined with carboxyl vinyl polymer induces strong neutralizing antibody, anti-HBs IgA, and IFNG response.鼻腔内接种 HBs 和 HBc 蛋白与羧基乙烯基聚合物可诱导产生强烈的中和抗体、抗-HBs IgA 和 IFNG 反应。
Biochem Biophys Res Commun. 2019 Nov 26;520(1):86-92. doi: 10.1016/j.bbrc.2019.09.072. Epub 2019 Sep 30.
6
Restoring, releasing or replacing adaptive immunity in chronic hepatitis B.恢复、释放或重建慢性乙型肝炎的适应性免疫。
Nat Rev Gastroenterol Hepatol. 2019 Nov;16(11):662-675. doi: 10.1038/s41575-019-0196-9. Epub 2019 Sep 23.
7
Therapeutic strategies for hepatitis B virus infection: towards a cure.乙型肝炎病毒感染的治疗策略：迈向治愈。
Nat Rev Drug Discov. 2019 Nov;18(11):827-844. doi: 10.1038/s41573-019-0037-0. Epub 2019 Aug 27.
8
Effects of pegylated interferon-α based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B.聚乙二醇干扰素-α 类治疗对慢性乙型肝炎患者功能性治愈和肝细胞癌发展风险的影响。
J Viral Hepat. 2019 Jul;26 Suppl 1:5-31. doi: 10.1111/jvh.13150.
9
Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial.治疗性疫苗TG1050在慢性乙型肝炎患者中的安全性和免疫原性：一项1b期安慰剂对照试验。
Hum Vaccin Immunother. 2020;16(2):388-399. doi: 10.1080/21645515.2019.1651141. Epub 2019 Oct 4.
10
Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study.尼伏单抗联合或不联合治疗性疫苗治疗病毒抑制慢性乙型肝炎的抗 PD-1 阻断：一项初步研究。
J Hepatol. 2019 Nov;71(5):900-907. doi: 10.1016/j.jhep.2019.06.028. Epub 2019 Jul 12.
Zotero 插件